GB201704909D0 - Cancer therapy - Google Patents

Cancer therapy

Info

Publication number
GB201704909D0
GB201704909D0 GBGB1704909.9A GB201704909A GB201704909D0 GB 201704909 D0 GB201704909 D0 GB 201704909D0 GB 201704909 A GB201704909 A GB 201704909A GB 201704909 D0 GB201704909 D0 GB 201704909D0
Authority
GB
United Kingdom
Prior art keywords
cancer therapy
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1704909.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LDN Pharma Ltd
Original Assignee
LDN Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LDN Pharma Ltd filed Critical LDN Pharma Ltd
Priority to GBGB1704909.9A priority Critical patent/GB201704909D0/en
Publication of GB201704909D0 publication Critical patent/GB201704909D0/en
Priority to JP2020503373A priority patent/JP7282072B2/ja
Priority to PCT/GB2018/050820 priority patent/WO2018178668A1/en
Priority to CN201880035454.9A priority patent/CN110740751A/zh
Priority to EP18715907.4A priority patent/EP3600431B1/en
Priority to US16/499,168 priority patent/US11304943B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1704909.9A 2017-03-28 2017-03-28 Cancer therapy Ceased GB201704909D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1704909.9A GB201704909D0 (en) 2017-03-28 2017-03-28 Cancer therapy
JP2020503373A JP7282072B2 (ja) 2017-03-28 2018-03-28 肺がんの治療に使用するための組み合わせ
PCT/GB2018/050820 WO2018178668A1 (en) 2017-03-28 2018-03-28 A combination for use in the treatment of lung cancer
CN201880035454.9A CN110740751A (zh) 2017-03-28 2018-03-28 用于治疗肺癌的结合物
EP18715907.4A EP3600431B1 (en) 2017-03-28 2018-03-28 A combination for use in the treatment of lung cancer
US16/499,168 US11304943B2 (en) 2017-03-28 2018-03-28 Combination for use in the treatment of lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1704909.9A GB201704909D0 (en) 2017-03-28 2017-03-28 Cancer therapy

Publications (1)

Publication Number Publication Date
GB201704909D0 true GB201704909D0 (en) 2017-05-10

Family

ID=58688080

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1704909.9A Ceased GB201704909D0 (en) 2017-03-28 2017-03-28 Cancer therapy

Country Status (6)

Country Link
US (1) US11304943B2 (ru)
EP (1) EP3600431B1 (ru)
JP (1) JP7282072B2 (ru)
CN (1) CN110740751A (ru)
GB (1) GB201704909D0 (ru)
WO (1) WO2018178668A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
CN114533871A (zh) * 2020-11-19 2022-05-27 中国科学院上海营养与健康研究所 靶向plk3在防治皮肤增生性疾病中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
FR2759586B1 (fr) * 1997-02-20 2000-01-14 Paul Trouillas Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol
CH693625A5 (it) * 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
US6384044B1 (en) 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
CN1802349A (zh) 2003-06-11 2006-07-12 诺瓦西股份有限公司 用活性维生素d化合物和其他治疗一起治疗肺癌
JP2007502867A (ja) * 2003-06-11 2007-02-15 ノバセア インコーポレイティッド 他の治療法と併用した、活性ビタミンｄ化合物による肺癌の治療法
CA2604887A1 (en) * 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
AU2006275914A1 (en) 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
CN101321554A (zh) 2005-09-30 2008-12-10 Tti优而美株式会社 使用类阿片激动剂和/或类阿片拮抗剂的经皮药物输送系统、装置和方法
EP2012772A1 (en) 2006-04-26 2009-01-14 The Uab Research Foundation Reducing cancer cell invasion using an inhibitor of toll like receptor signaling
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US8479760B2 (en) * 2010-06-30 2013-07-09 Easy Solutions Technologies, Inc. Air conditioner water pan drain line system
JP2015107918A (ja) * 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
BR112015004165A2 (pt) 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
GB201410216D0 (en) * 2014-06-09 2014-07-23 Cancer Vaccine Inst Therapeutic
EP3206491B1 (en) * 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression

Also Published As

Publication number Publication date
EP3600431A1 (en) 2020-02-05
US11304943B2 (en) 2022-04-19
EP3600431B1 (en) 2022-11-23
JP7282072B2 (ja) 2023-05-26
CN110740751A (zh) 2020-01-31
JP2020512408A (ja) 2020-04-23
US20200101064A1 (en) 2020-04-02
WO2018178668A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination for cancer treatment
IL254705B (en) Combined treatment for cancer
SI3423087T1 (sl) Kombinirana terapija proti raku
GB201707153D0 (en) Therapy
HK1258319A1 (zh) 癌症療法
ZA202005847B (en) Cancer therapy
PT3576740T (pt) Tratamento de cancro
IL268463A (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
IL274626A (en) Cancer treatment
GB201519734D0 (en) Cancer therapy
GB201704909D0 (en) Cancer therapy
HK1254687A1 (zh) 用於癌症的聯合療法
GB201711855D0 (en) Cancer therapy
GB201711250D0 (en) Cancer therapy
HRP20210383T8 (hr) Kombinirana terapija za rak
GB201710198D0 (en) Cancer therapy
GB201706046D0 (en) Cancer therapy
GB201700772D0 (en) Cancer therapy
GB201806463D0 (en) Cancer therapy
GB201713852D0 (en) Cancer treatment
GB201720533D0 (en) Cancer treatments
GB201601248D0 (en) Cancer therapy
GB201707183D0 (en) Macrophage-based therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)